We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $762M
1-Year Est. Return 1,125.36%
This Fund
S&P 500
This Quarter Est. Return
+136.72%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$314M
AUM Growth
+$115M
Cap. Flow
+$11.9M
Cap. Flow %
3.81%
Top 10 Hldgs %
75.24%
Holding
35
New
15
Increased
2
Reduced
9
Closed
1

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$13M
2
PTCT icon
PTC Therapeutics
PTCT
+$10.4M
3
CYTK icon
Cytokinetics
CYTK
+$8.24M
4
ABVX
Abivax
ABVX
+$7.36M
5
INO icon
Inovio Pharmaceuticals
INO
+$4.4M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$16M
2
RVMD icon
Revolution Medicines
RVMD
+$15.4M
3
ITOS
iTeos Therapeutics
ITOS
+$8.23M
4
REPL icon
Replimune Group
REPL
+$7.42M
5
KYMR icon
Kymera Therapeutics
KYMR
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.41B
$1.62M 0.52%
175,000
– –
AVTX icon
27
Avalo Therapeutics
AVTX
$965M
$1.59M 0.51%
+125,000
New +$1.08M
MIST icon
28
Milestone Pharmaceuticals
MIST
$138M
$1.33M 0.43%
+666,666
New +$1.17M
PEPG icon
29
PepGen
PEPG
$122M
$1.16M 0.37%
+250,000
New +$403K
LBRX
30
LB Pharmaceuticals
LBRX
$1.15B
$1.11M 0.35%
+70,000
New +$1.11M
TIL icon
31
Instil Bio
TIL
$48.3M
$1.08M 0.35%
60,700
-10,000
-14% -$254K
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
$248K 0.08%
20,400
-73,000
-78% -$1.01M
NUVB.WS
33
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$53.9K 0.02%
266,666
– –
SRZNW icon
34
Surrozen Inc Warrant
SRZNW
$1K ﹤0.01%
66,666
– –
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
– –
-825,000
Closed -$8.23M
1
2

Similar funds

GWM
Gibbs Wealth Management Alpharetta, Georgia $762M AUM 18.55% 1-Year Est. Return
FTF
Freedom Together Foundation New York $762M AUM 15.13% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
CFS
Cannon Financial Strategists Athens, Georgia $761M AUM 18.73% 1-Year Est. Return
PMWMG
Parr McKnight Wealth Management Group Minneapolis, Minnesota $763M AUM 13.49% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CCIP
Camrose Capital Investment Partners London, United Kingdom $764M AUM 0.9% 1-Year Est. Return

Boxer Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Boxer Capital Management held 35 positions worth $314M, up 58% from $199M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Boxer Capital Management deployed $11.9M of net new capital in Q3 2025, opening 15 new positions and adding to 2 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 250,000 shares worth $1.79M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $16M trimmed.

  • Boxer Capital Management's largest Q3 2025 buy was MoonLake Immunotherapeutics: 250,000 shares worth $1.79M.
  • Boxer Capital Management added most to Sarepta Therapeutics in Q3 2025, an estimated $4.01M increase.
  • Boxer Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $16M.
  • Boxer Capital Management fully exited iTeos Therapeutics in Q3 2025, selling an estimated $8.23M.
  • Boxer Capital Management's ten largest holdings make up 75% of its $314M portfolio in Q3 2025.
  • Boxer Capital Management opened 15 new positions and closed 1 in Q3 2025.
  • Boxer Capital Management's portfolio value rose 58% quarter-over-quarter to $314M.

Based on Boxer Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.